Cargando…

Electrochemotherapy Is Effective in the Treatment of Bone Metastases

Bone metastases induce pain, risk of fracture, and neural compression, and reduced mobility and quality of life. Electrochemotherapy (ECT) is a minimally invasive local treatment based on a high-voltage electric pulse combined with an anticancer drug. Preclinical and clinical studies have supported...

Descripción completa

Detalles Bibliográficos
Autores principales: Campanacci, Laura, Cevolani, Luca, De Terlizzi, Francesca, Saenz, Laura, Alì, Nikolin, Bianchi, Giuseppe, Donati, Davide Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947745/
https://www.ncbi.nlm.nih.gov/pubmed/35323339
http://dx.doi.org/10.3390/curroncol29030139
_version_ 1784674512763092992
author Campanacci, Laura
Cevolani, Luca
De Terlizzi, Francesca
Saenz, Laura
Alì, Nikolin
Bianchi, Giuseppe
Donati, Davide Maria
author_facet Campanacci, Laura
Cevolani, Luca
De Terlizzi, Francesca
Saenz, Laura
Alì, Nikolin
Bianchi, Giuseppe
Donati, Davide Maria
author_sort Campanacci, Laura
collection PubMed
description Bone metastases induce pain, risk of fracture, and neural compression, and reduced mobility and quality of life. Electrochemotherapy (ECT) is a minimally invasive local treatment based on a high-voltage electric pulse combined with an anticancer drug. Preclinical and clinical studies have supported the use of ECT in patients with metastatic bone disease, demonstrating that it does not damage the mineral structure of the bone and its regenerative capacity, and that is feasible and efficient for the treatment of bone metastases. Since 2009, 88 patients with bone metastasis have received ECT at the Rizzoli Institute. 2014 saw the start of a registry of patients with bone metastases treated with ECT, whose data are recorded in a shared database. We share the Rizzoli Institute experience of 38 patients treated with ECT for a bone metastasis, excluding patients not included in the registry (before 2014) and those treated with bone fixation. Mean follow-up was 2 months (1–52). Response to treatment using RECIST criteria was 29% objective responses, 59% stable disease, and 16% progressive disease. Using PERCIST, the response was 36% OR, 14% SD, and 50% PD with no significant differences between the two criteria. A significant decrease in pain and better quality of life was observed at FU.
format Online
Article
Text
id pubmed-8947745
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89477452022-03-25 Electrochemotherapy Is Effective in the Treatment of Bone Metastases Campanacci, Laura Cevolani, Luca De Terlizzi, Francesca Saenz, Laura Alì, Nikolin Bianchi, Giuseppe Donati, Davide Maria Curr Oncol Article Bone metastases induce pain, risk of fracture, and neural compression, and reduced mobility and quality of life. Electrochemotherapy (ECT) is a minimally invasive local treatment based on a high-voltage electric pulse combined with an anticancer drug. Preclinical and clinical studies have supported the use of ECT in patients with metastatic bone disease, demonstrating that it does not damage the mineral structure of the bone and its regenerative capacity, and that is feasible and efficient for the treatment of bone metastases. Since 2009, 88 patients with bone metastasis have received ECT at the Rizzoli Institute. 2014 saw the start of a registry of patients with bone metastases treated with ECT, whose data are recorded in a shared database. We share the Rizzoli Institute experience of 38 patients treated with ECT for a bone metastasis, excluding patients not included in the registry (before 2014) and those treated with bone fixation. Mean follow-up was 2 months (1–52). Response to treatment using RECIST criteria was 29% objective responses, 59% stable disease, and 16% progressive disease. Using PERCIST, the response was 36% OR, 14% SD, and 50% PD with no significant differences between the two criteria. A significant decrease in pain and better quality of life was observed at FU. MDPI 2022-03-04 /pmc/articles/PMC8947745/ /pubmed/35323339 http://dx.doi.org/10.3390/curroncol29030139 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Campanacci, Laura
Cevolani, Luca
De Terlizzi, Francesca
Saenz, Laura
Alì, Nikolin
Bianchi, Giuseppe
Donati, Davide Maria
Electrochemotherapy Is Effective in the Treatment of Bone Metastases
title Electrochemotherapy Is Effective in the Treatment of Bone Metastases
title_full Electrochemotherapy Is Effective in the Treatment of Bone Metastases
title_fullStr Electrochemotherapy Is Effective in the Treatment of Bone Metastases
title_full_unstemmed Electrochemotherapy Is Effective in the Treatment of Bone Metastases
title_short Electrochemotherapy Is Effective in the Treatment of Bone Metastases
title_sort electrochemotherapy is effective in the treatment of bone metastases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947745/
https://www.ncbi.nlm.nih.gov/pubmed/35323339
http://dx.doi.org/10.3390/curroncol29030139
work_keys_str_mv AT campanaccilaura electrochemotherapyiseffectiveinthetreatmentofbonemetastases
AT cevolaniluca electrochemotherapyiseffectiveinthetreatmentofbonemetastases
AT deterlizzifrancesca electrochemotherapyiseffectiveinthetreatmentofbonemetastases
AT saenzlaura electrochemotherapyiseffectiveinthetreatmentofbonemetastases
AT alinikolin electrochemotherapyiseffectiveinthetreatmentofbonemetastases
AT bianchigiuseppe electrochemotherapyiseffectiveinthetreatmentofbonemetastases
AT donatidavidemaria electrochemotherapyiseffectiveinthetreatmentofbonemetastases